Same-Day Sedative and Night-Time Sleep Effects Following Combined Cannabinoid Formulations: A Randomised-Controlled Trial
Open Access
- 21 June 2025
- journal article
- research article
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 45 (7) , 417-429
Abstract
Background and objectives Cannabinoid treatments are commonly used for sleep conditions, but the direct sedating effects of daytime treatment consumption and indirect effects on night-time sleep are unclear. This study measures the direct effects of low-dose cannabinoid treatments on daytime sleepiness and potential indirect night-time sleep effects in healthy adult, novice cannabis users. Methods Using a double-blind, randomised, placebo-controlled cross-over design, participants were orally administered a standardised dose of 1 mL oil containing THC:CBD ratios of either 1:1, 1:16 or a placebo over five weekly in-lab visits. Daytime sleepiness was measured at 40, 135 and 265 min post-dosing using the Karolinska Sleepiness Scale (KSS). Indirect night-time sleep effects on total sleep time (TST), sleep-onset latency (SOL), and number of awakenings after onset were measured using daily wrist-actigraphy and sleep-diary entries during the 7-day washout period between treatments. Results Final analyses (N = 20) showed subjective sleepiness (KSS score) significantly increased (mean difference = 1.9, SE 0.25) from 40 min to 265 min post-treatment (p < 0.001). No significant differences were observed between treatments for KSS. Indirect sleep measures (TST, SOL, number of awakenings) showed no differences between treatments or over time (all p > 0.05). Conclusion Daytime consumption of low-dose cannabinoid oils did not induce direct sleepiness or indirect night-time effects post-dosing among adults. Future studies would benefit from exploring pharmacokinetics and the possibility of treatment amplification of daytime fatigue, mood and cognitive changes to assist the development of therapeutic guidelines for safe daytime medical cannabis use. ANCTR Trial Registration Number ACTRN12622001539729, 13 December 2022, prospectively registered.Keywords
Funding Information
- Rebecca L. Cooper Medical Research Foundation (F2021894)
- Australian Office of Road Safety (RSIF2-51)
- Swinburne University of Technology
This publication has 40 references indexed in Scilit:
- Evaluating possible ‘next day’ impairment in insomnia patients administered an oral medicinal cannabis product by night: a pilot randomized controlled trialPsychopharmacology, 2024
- Cannabinoids: Emerging sleep modulatorBiomedicine & Pharmacotherapy, 2023
- Cannabinoid treatments for anxiety: A systematic review and consideration of the impact of sleep disturbanceNeuroscience & Biobehavioral Reviews, 2022
- Tetrahydrocannabinol and cannabidiol medicines for chronic pain and mental health conditionsInflammopharmacology, 2022
- Pharmacodynamic effects of vaporized and oral cannabidiol (CBD) and vaporized CBD-dominant cannabis in infrequent cannabis usersDrug and Alcohol Dependence, 2020
- A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy SubjectsCNS Drugs, 2018
- Cannabis, Pain, and Sleep: Lessons from Therapeutic Clinical Trials of Sativex®, a Cannabis‐Based MedicineChemistry & Biodiversity, 2007
- Validation of the Karolinska sleepiness scale against performance and EEG variablesClinical Neurophysiology, 2006
- Examination of the utility of the Beck Anxiety Inventory and its factors as a screener for anxiety disordersJournal of Anxiety Disorders, 2006
- Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDSJournal of Pain and Symptom Management, 1995